CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 471 filers reported holding CRISPR THERAPEUTICS AG in Q3 2021. The put-call ratio across all filers is 1.71 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $491,000 | -29.3% | 4,387 | +2.3% | 0.31% | -29.3% |
| Q2 2021 | $694,000 | +42.8% | 4,287 | +7.5% | 0.44% | +30.7% |
| Q1 2021 | $486,000 | -15.3% | 3,987 | +6.4% | 0.34% | -19.3% |
| Q4 2020 | $574,000 | +600.0% | 3,747 | +61.7% | 0.42% | +475.3% |
| Q1 2019 | $82,000 | +24.2% | 2,317 | 0.0% | 0.07% | +9.0% |
| Q4 2018 | $66,000 | -60.9% | 2,317 | -39.3% | 0.07% | -56.2% |
| Q3 2018 | $169,000 | -67.4% | 3,817 | -56.7% | 0.15% | -69.6% |
| Q2 2018 | $518,000 | +65.5% | 8,817 | +28.8% | 0.50% | +61.0% |
| Q1 2018 | $313,000 | -53.4% | 6,846 | -76.1% | 0.31% | -50.9% |
| Q4 2017 | $671,000 | – | 28,591 | – | 0.64% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |